Search Results - "Iwata, Hiroji"

Adjuvant and neoadjuvant therapy for breast cancer by Shien, Tadahiko, Iwata, Hiroji

“…Abstract Systemic therapies for operable breast cancer patients have improved outcomes and have thus become standard treatments. Recently, new molecular target…”
Get full text

Clinical development of CDK4/6 inhibitor for breast cancer by Iwata, Hiroji

“…Endocrine therapy is the mainstay of treatment for patients with estrogen receptor positive (ER+)/HER2-negative (HER2−) metastatic breast cancer (MBC). Many…”
Get full text

Alpelisib for PIK3CA-Mutated, Hormone Receptor–Positive Advanced Breast Cancer by André, Fabrice, Ciruelos, Eva, Rubovszky, Gabor, Campone, Mario, Loibl, Sibylle, Rugo, Hope S, Iwata, Hiroji, Conte, Pierfranco, Mayer, Ingrid A, Kaufman, Bella, Yamashita, Toshinari, Lu, Yen-Shen, Inoue, Kenichi, Takahashi, Masato, Pápai, Zsuzsanna, Longin, Anne-Sophie, Mills, David, Wilke, Celine, Hirawat, Samit, Juric, Dejan

“…PIK3CA mutations occur in approximately 40% of patients with hormone receptor–positive breast cancer. A PI3K inhibitor, alpelisib, combined with fulvestrant…”
Get full text

Palbociclib in Hormone-Receptor–Positive Advanced Breast Cancer by Turner, Nicholas C, Ro, Jungsil, André, Fabrice, Loi, Sherene, Verma, Sunil, Iwata, Hiroji, Harbeck, Nadia, Loibl, Sibylle, Huang Bartlett, Cynthia, Zhang, Ke, Giorgetti, Carla, Randolph, Sophia, Koehler, Maria, Cristofanilli, Massimo

“…In women with hormone-receptor–positive metastatic breast cancer that had progressed after endocrine therapy, palbociclib plus fulvestrant was associated with…”
Get full text

Current approach and future perspective for ductal carcinoma in situ of the breast by Kanbayashi, Chizuko, Iwata, Hiroji

“…Ductal carcinoma in situ (DCIS) has a good prognosis with the current treatment approach, with a 10-year breast cancer-specific survival rate of 97-98%. In…”
Get full text

MONARCH 3 final PFS: a randomized study of abemaciclib as initial therapy for advanced breast cancer by Johnston, Stephen, Martin, Miguel, Di Leo, Angelo, Im, Seock-Ah, Awada, Ahmad, Forrester, Tammy, Frenzel, Martin, Hardebeck, Molly C., Cox, Joanne, Barriga, Susana, Toi, Masakazu, Iwata, Hiroji, Goetz, Matthew P.

“…At the MONARCH 3 interim analysis, abemaciclib plus a nonsteroidal aromatase inhibitor (AI) significantly improved progression-free survival (PFS) and…”
Get full text

Functions of Breast Cancer Predisposition Genes: Implications for Clinical Management by Yoshimura, Akiyo, Imoto, Issei, Iwata, Hiroji

“…Approximately 5–10% of all breast cancer (BC) cases are caused by germline pathogenic variants (GPVs) in various cancer predisposition genes (CPGs). The most…”
Get full text

Trastuzumab Deruxtecan in Previously Treated HER2-Positive Breast Cancer by Modi, Shanu, Saura, Cristina, Yamashita, Toshinari, Park, Yeon Hee, Kim, Sung-Bae, Tamura, Kenji, Andre, Fabrice, Iwata, Hiroji, Ito, Yoshinori, Tsurutani, Junji, Sohn, Joohyuk, Denduluri, Neelima, Perrin, Christophe, Aogi, Kenjiro, Tokunaga, Eriko, Im, Seock-Ah, Lee, Keun Seok, Hurvitz, Sara A, Cortes, Javier, Lee, Caleb, Chen, Shuquan, Zhang, Lin, Shahidi, Javad, Yver, Antoine, Krop, Ian

“…In this single-group, phase 2 study, the use of trastuzumab deruxtecan resulted in a response in 60% of women with HER2-positive advanced breast cancer who had…”
Get full text

Pembrolizumab plus Chemotherapy in Advanced Triple-Negative Breast Cancer by Cortes, Javier, Rugo, Hope S., Cescon, David W., Im, Seock-Ah, Yusof, Mastura M., Gallardo, Carlos, Lipatov, Oleg, Barrios, Carlos H., Perez-Garcia, Jose, Iwata, Hiroji, Masuda, Norikazu, Torregroza Otero, Marco, Gokmen, Erhan, Loi, Sherene, Guo, Zifang, Zhou, Xuan, Karantza, Vassiliki, Pan, Wilbur, Schmid, Peter

“…Among patients with triple-negative breast cancer and high expression of PD-L1, pembrolizumab plus chemotherapy resulted in longer overall survival than…”
Get full text

Atezolizumab and Nab-Paclitaxel in Advanced Triple-Negative Breast Cancer by Schmid, Peter, Adams, Sylvia, Rugo, Hope S, Schneeweiss, Andreas, Barrios, Carlos H, Iwata, Hiroji, Diéras, Véronique, Hegg, Roberto, Im, Seock-Ah, Shaw Wright, Gail, Henschel, Volkmar, Molinero, Luciana, Chui, Stephen Y, Funke, Roel, Husain, Amreen, Winer, Eric P, Loi, Sherene, Emens, Leisha A

“…Addition of the anti–PD-L1 antibody atezolizumab to nab-paclitaxel as first-line therapy for patients with advanced or metastatic triple-negative breast cancer…”
Get full text

Overall Survival with Palbociclib and Fulvestrant in Advanced Breast Cancer by Turner, Nicholas C, Slamon, Dennis J, Ro, Jungsil, Bondarenko, Igor, Im, Seock-Ah, Masuda, Norikazu, Colleoni, Marco, DeMichele, Angela, Loi, Sherene, Verma, Sunil, Iwata, Hiroji, Harbeck, Nadia, Loibl, Sibylle, André, Fabrice, Puyana Theall, Kathy, Huang, Xin, Giorgetti, Carla, Huang Bartlett, Cynthia, Cristofanilli, Massimo

“…The addition of palbociclib to fulvestrant prolonged overall survival among women with hormone receptor–positive, HER2-negative advanced breast cancer who had…”
Get full text

Atezolizumab and nab-Paclitaxel in Advanced Triple-Negative Breast Cancer: Biomarker Evaluation of the IMpassion130 Study by Emens, Leisha A, Molinero, Luciana, Loi, Sherene, Rugo, Hope S, Schneeweiss, Andreas, Diéras, Véronique, Iwata, Hiroji, Barrios, Carlos H, Nechaeva, Marina, Nguyen-Duc, Anh, Chui, Stephen Y, Husain, Amreen, Winer, Eric P, Adams, Sylvia, Schmid, Peter

“…Abstract Background Understanding the impact of the tumor immune microenvironment and BRCA1/2-related DNA repair deficiencies on the clinical activity of…”
Get full text

Abemaciclib plus endocrine therapy for hormone receptor-positive, HER2-negative, node-positive, high-risk, early breast cancer by Nozawa, Kazuki, Sawaki, Masataka, Iwata, Hiroji

Get full text

Adjuvant Capecitabine for Breast Cancer after Preoperative Chemotherapy by Masuda, Norikazu, Lee, Soo-Jung, Ohtani, Shoichiro, Im, Young-Hyuck, Lee, Eun-Sook, Yokota, Isao, Kuroi, Katsumasa, Im, Seock-Ah, Park, Byeong-Woo, Kim, Sung-Bae, Yanagita, Yasuhiro, Ohno, Shinji, Takao, Shintaro, Aogi, Kenjiro, Iwata, Hiroji, Jeong, Joon, Kim, Aeree, Park, Kyong-Hwa, Sasano, Hironobu, Ohashi, Yasuo, Toi, Masakazu

“…Patients who complete neoadjuvant chemotherapy for breast cancer without a pathological complete response have a high risk of relapse. A randomized trial…”
Get full text

Current status of PD-1/PD-L1 blockade immunotherapy in breast cancer by Noguchi, Emi, Shien, Tadahiko, Iwata, Hiroji

“…Abstract Over the past 10 years, immunotherapy with immune checkpoint inhibitors has revolutionized the management of various cancers. However, immunotherapy…”
Get full text

Real-world treatment patterns of subsequent therapy after palbociclib in patients with advanced breast cancer in Japan by Sawaki, Masataka, Muramatsu, Yasuaki, Togo, Kanae, Iwata, Hiroji

“…The optimal treatment following endocrine therapy (ET) plus a cyclin-dependent kinase 4/6 inhibitor (CDK4/6i) has not been established. We aimed to investigate…”
Get full text

Fulvestrant plus palbociclib versus fulvestrant plus placebo for treatment of hormone-receptor-positive, HER2-negative metastatic breast cancer that progressed on previous endocrine therapy (PALOMA-3): final analysis of the multicentre, double-blind, phase 3 randomised controlled trial by Cristofanilli, Massimo, Prof, Turner, Nicholas C, MD, Bondarenko, Igor, Prof, Ro, Jungsil, MD, Im, Seock-Ah, MD, Masuda, Norikazu, MD, Colleoni, Marco, MD, DeMichele, Angela, MD, Loi, Sherene, MD, Verma, Sunil, MD, Iwata, Hiroji, MD, Harbeck, Nadia, Prof, Zhang, Ke, PhD, Theall, Kathy Puyana, MD, Jiang, Yuqiu, PhD, Bartlett, Cynthia Huang, MD, Koehler, Maria, MD, Slamon, Dennis, Prof

“…Summary Background In the PALOMA-3 study, the combination of the CDK4 and CDK6 inhibitor palbociclib and fulvestrant was associated with significant…”
Get full text

TNM classification of malignant tumors (Breast Cancer Study Group) by Sawaki, Masataka, Shien, Tadahiko, Iwata, Hiroji

“…The eighth editions of the primary tumor, lymph node and metastasis classifications were recently published. We review the points of change and discuss…”
Get full text

Management of breast cancer in older patients by Sawaki, Masataka, Shimomura, Akihiko, Shien, Tadahiko, Iwata, Hiroji

“…Abstract Japanese women have the highest life expectancy in the world and breast cancer is the most prevalent cancer among them. However, little data are…”
Get full text

The frequency of low HER2 expression in breast cancer and a comparison of prognosis between patients with HER2-low and HER2-negative breast cancer by HR status by Horisawa, Nanae, Adachi, Yayoi, Takatsuka, Daiki, Nozawa, Kazuki, Endo, Yuka, Ozaki, Yuri, Sugino, Kayoko, Kataoka, Ayumi, Kotani, Haruru, Yoshimura, Akiyo, Hattori, Masaya, Sawaki, Masataka, Iwata, Hiroji

“…Purpose The DESTINY-Breast04 clinical trial is currently investigating whether trastuzumab deruxtecan (T-DXd) is effective in HER2-low as well as HER2-positive…”
Get full text